Dimeric and trimeric fusion proteins generated with fimbrial adhesins of uropathogenic Escherichia coli

Frontiers in Cellular and Infection Microbiology

Volumn 6, Issue OCT, 2016, Pages

  Luna Pineda, Víctor M ^a,b   Reyes Grajeda, Juan Pablo ^c   Cruz Córdova, Ariadnna ^a   Saldaña Ahuactzi, Zeus ^a,b   Ochoa, Sara A ^a   Maldonado Bernal, Carmen ^a   Cázares Domínguez, Vicenta ^a   Moreno Fierros, Leticia ^d   Arellano Galindo, José ^a   Hernández Castro, Rigoberto ^e   Xicohtencatl Cortes, Juan ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^c INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

Author keywords

Cytokines; Fimbrial adhesin; Fusion protein; UPEC; UTIs

Indexed keywords

CURLI FIMBRIAE PROTEIN; FIMBRIA PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 8; MEMBRANE FUSION PROTEIN; UNCLASSIFIED DRUG; ADHESIN; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; CSGA PROTEIN, E COLI; CYTOKINE; ESCHERICHIA COLI PROTEIN; ESCHERICHIA COLI VACCINE; FIMH PROTEIN, E COLI; HYBRID PROTEIN; PAPG PROTEIN, E COLI; RECOMBINANT VACCINE;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; FIMBRIA; GENE EXPRESSION; GENE SEQUENCE; GENE SYNTHESIS; IMMUNOGENICITY; MASS SPECTROMETRY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; WESTERN BLOTTING; ANIMAL; BLOOD; CELL LINE; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; HUMAN; IMMUNOLOGY; LEPORIDAE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MICROBIOLOGY; MOLECULAR WEIGHT; PHOTON CORRELATION SPECTROSCOPY; SECRETION (PROCESS); URINE;

ADHESINS, ESCHERICHIA COLI; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL ADHESION; CELL LINE; CYTOKINES; DYNAMIC LIGHT SCATTERING; EPITHELIAL CELLS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FIMBRIAE PROTEINS; HUMANS; MOLECULAR WEIGHT; RABBITS; RECOMBINANT FUSION PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UROPATHOGENIC ESCHERICHIA COLI; VACCINES, SYNTHETIC;

EID: 84997235052     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2016.00135     Document Type: Article

References (84)

1. Akira, S., Takeda, K., and Kaisho, T. (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2, 675-680. doi: 10.1038/90609.
2. Andrews, B., Adari, H., Hannig, G., Lahue, E., Gosselin, M., Martin, S., et al. (1996). A tightly regulated high level expression vector that utilizes a thermosensitive lac repressor: production of the human T cell receptor V beta 5.3 in Escherichia coli. Gene 182, 101-109. doi: 10.1016/S0378-1119(96)00523-9.
3. Antão, E.-M., Wieler, L. H., and Ewers, C. (2009). Adhesive threads of extraintestinal pathogenic Escherichia coli. Gut Pathog. 1:22. doi: 10.1186/1757-4749-1-22.
4. Arai, R., Wriggers, W., Nishikawa, Y., Nagamune, T., and Fujisawa, T. (2004). Conformations of variably linked chimeric proteins evaluated by synchrotron X-ray small-angle scattering. Proteins 57, 829-838. doi: 10.1002/prot.20244.
5. Asadi Karam, M. R., Oloomi, M., Mahdavi, M., Habibi, M., and Bouzari, S. (2013). Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine 31, 1210-1216. doi: 10.1016/j.vaccine.2012.12.059.
6. Biedenbach, D. J., Badal, R. E., Huang, M.-Y., Motyl, M., Singhal, P. K., Kozlov, R. S., et al. (2016). In Vitro activity of oral antimicrobial agents against pathogens associated with community-acquired upper respiratory tract and urinary tract infections: a five country surveillance study. Infect. Dis. Ther. 5, 139-153. doi: 10.1007/s40121-016-0112-3.
7. Brinkmann, U., Mattes, R. E., and Buckel, P. (1989). High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene 85, 109-114. doi: 10.1016/0378-1119(89)90470-8.
8. Brumbaugh, A. R., and Mobley, H. L. T. (2012). Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev. Vaccines 11, 663-676. doi: 10.1586/erv.12.36.
9. Chen, J., Liu, H., Yang, J., and Chou, K.-C. (2007). Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids 33, 423-428. doi: 10.1007/s00726-006-0485-9.
10. Chen, X., Zaro, J. L., and Shen, W.-C. (2013). Fusion protein linkers: property, design and functionality. Adv. Drug Deliv. Rev. 65, 1357-1369. doi: 10.1016/j.addr.2012.09.039.
11. Cheng, L., Chen, Q., Zhu, W., Wu, H., Wang, Q., Shi, L., et al. (2016). Toll-like receptors 4 and 5 cooperatively initiate the innate immune responses to uropathogenic E. coli infection in mouse epididymal epithelial cells. Biol. Reprod. 94:58. doi: 10.1095/biolreprod.115.136580.
12. Datsenko, K. A., and Wanner, B. L. (2000). One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U.S.A. 97, 6640-6645. doi: 10.1073/pnas.120163297.
13. De Groot, A. S., and Moise, L. (2007). New tools, new approaches and new ideas for vaccine development. Expert Rev. Vaccines 6, 125-127. doi: 10.1586/14760584.6.2.125.
14. De Groot, A. S., Sbai, H., Aubin, C. S., McMurry, J., and Martin, W. (2002). Immuno-informatics: mining genomes for vaccine components. Immunol. Cell Biol. 80, 255-269. doi: 10.1046/j.1440-1711.2002.01092.x.
15. Fischer, H., Yamamoto, M., Akira, S., Beutler, B., and Svanborg, C. (2006). Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection. Eur. J. Immunol. 36, 267-277. doi: 10.1002/eji.200535149.
16. Flores-Mireles, A. L., Walker, J. N., Caparon, M., and Hultgren, S. J. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269-284. doi: 10.1038/nrmicro3432.
17. Foxman, B. (2002). Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 113(Suppl. 1A), 5S-13S. doi: 10.1016/s0002-9343(02)01054-9.
18. Foxman, B. (2010). The epidemiology of urinary tract infection. Nat. Rev. Urol. 7, 653-660. doi: 10.1038/nrurol.2010.190.
19. Foxman, B. (2014). Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. North Am. 28, 1-13. doi: 10.1016/j.idc.2013.09.003.
20. Frendéus, B., Wachtler, C., Hedlund, M., Fischer, H., Samuelsson, P., Svensson, M., et al. (2001). Escherichia coli P fimbriae utilize the Toll-like receptor 4 pathway for cell activation. Mol. Microbiol. 40, 37-51. doi: 10.1046/j.1365-2958.2001.02361.x.
21. Golshani, M., Rafati, S., Jahanian-Najafabadi, A., Nejati-Moheimani, M., Siadat, S. D., Shahcheraghi, F., et al. (2015). In silico design, cloning and high level expression of L7/L12-TOmp31 fusion protein of Brucella antigens. Res. Pharm. Sci. 10, 436-445.
22. Greene, S. E., Hibbing, M. E., Janetka, J., Chen, S. L., and Hultgren, S. J. (2015). Human urine decreases function and expression of type 1 pili in uropathogenic Escherichia coli. MBio 6:e00820. doi: 10.1128/mBio.00820-15.
23. Habibi, M., Asadi Karam, M. R., and Bouzari, S. (2015a). In silico design of fusion protein of FimH from uropathogenic Escherichia coli and MrpH from Proteus mirabilis against urinary tract infections. Adv. Biomed. Res. 4, 217. doi: 10.4103/2277-9175.166164.
24. Habibi, M., Asadi Karam, M. R., Shokrgozar, M. A., Oloomi, M., Jafari, A., and Bouzari, S. (2015b). Intranasal immunization with fusion protein MrpH FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis. Mol. Immunol. 64, 285-294. doi: 10.1016/j.molimm.2014.12.008.
25. Hagan, E. C., and Mobley, H. L. T. (2007). Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection. Infect. Immun. 75, 3941-3949. doi: 10.1128/IAI.00337-07.
26. Hannan, T. J., and Hunstad, D. A. (2016). A murine model for Escherichia coli urinary tract infection. Methods Mol. Biol. 1333, 159-175. doi: 10.1007/978-1-4939-2854-5_14.
27. Huang, Z., Li, G., Zhang, C., and Xing, X.-H. (2016). A study on the effects of linker flexibility on acid phosphatase PhoC-GFP fusion protein using a novel linker library. Enzyme Microb. Technol. 83, 1-6. doi: 10.1016/j.enzmictec.2015.11.002.
28. Huleatt, J. W., Jacobs, A. R., Tang, J., Desai, P., Kopp, E. B., Huang, Y., et al. (2007). Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25, 763-775. doi: 10.1016/j.vaccine.2006.08.013.
29. Hung, C., Marschall, J., Burnham, C.-A. D., Byun, A. S., and Henderson, J. P. (2014). The bacterial amyloid curli is associated with urinary source bloodstream infection. PLoS ONE 9:e86009. doi: 10.1371/journal.pone.0086009.
30. Hung, C.-S., Bouckaert, J., Hung, D., Pinkner, J., Widberg, C., DeFusco, A., et al. (2002). Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol. Microbiol. 44, 903-915. doi: 10.1046/j.1365-2958.2002.02915.x.
31. Ikai, A. (1980). Thermostability and aliphatic index of globular proteins. J. Biochem. 88, 1895-1898.
32. Janin, J., and Chothia, C. (1990). The structure of protein-protein recognition sites. J. Biol. Chem. 265, 16027-16030.
33. Kumar, S., Dave, A., Wolf, B., and Lerma, E. V. (2015). Urinary tract infections. Dis. Mon. 61, 45-59. doi: 10.1016/j.disamonth.2014.12.002.
34. Lane, M. C., and Mobley, H. L. T. (2007). Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int. 72, 19-25. doi: 10.1038/sj.ki.5002230.
35. Langermann, S., and Ballou, W. R. (2001). Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections. J. Infect. Dis. 183(Suppl. 1), S84-S86. doi: 10.1086/318857.
36. Langermann, S., Möllby, R., Burlein, J. E., Palaszynski, S. R., Auguste, C. G., DeFusco, A., et al. (2000). Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 181, 774-778. doi: 10.1086/315258.
37. Langermann, S., Palaszynski, S., Barnhart, M., Auguste, G., Pinkner, J. S., Burlein, J., et al. (1997). Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 276, 607-611. doi: 10.1126/science.276.5312.607.
38. Laskowski, R. A., MacArthur, M. W., and Thornton, J. M. (1998). Validation of protein models derived from experiment. Curr. Opin. Struct. Biol. 8, 631-639. doi: 10.1016/S0959-440X(98)80156-5.
39. Leatham-Jensen, M. P., Mokszycki, M. E., Rowley, D. C., Deering, R., Camberg, J. L., Sokurenko, E. V., et al. (2016). Uropathogenic Escherichia coli metabolite-dependent quiescence and persistence may explain antibiotic tolerance during urinary tract infection. mSphere 1:e00055-15. doi: 10.1128/mSphere.00055-15.
40. Ledesma, M. A., Ochoa, S. A., Cruz, A., Rocha-Ramírez, L. M., Mas-Oliva, J., Eslava, C. A., et al. (2010). The hemorrhagic coli pilus (HCP) of Escherichia coli O157:H7 is an inducer of proinflammatory cytokine secretion in intestinal epithelial cells. PLoS ONE 5:e12127. doi: 10.1371/journal.pone.0012127.
41. Li, G., Huang, Z., Zhang, C., Dong, B.-J., Guo, R.-H., Yue, H.-W., et al. (2016). Construction of a linker library with widely controllable flexibility for fusion protein design. Appl. Microbiol. Biotechnol. 100, 215-225. doi: 10.1007/s00253-015-6985-3.
42. Lim, J. Y., Pinkner, J. S., and Cegelski, L. (2014). Community behavior and amyloid-associated phenotypes among a panel of uropathogenic E. coli. Biochem. Biophys. Res. Commun. 443, 345-350. doi: 10.1016/j.bbrc.2013.11.026.
43. Luscombe, N. M., Greenbaum, D., and Gerstein, M. (2001). What is bioinformatics? A proposed definition and overview of the field. Methods Inform. Med. 40, 346-358.
44. Lüthje, P., and Brauner, A. (2014). Virulence factors of uropathogenic E. coli and their interaction with the host. Adv. Microb. Physiol. 65, 337-372. doi: 10.1016/bs.ampbs.2014.08.006.
45. Melzer, M., and Petersen, I. (2007). Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J. Infect. 55, 254-259. doi: 10.1016/j.jinf.2007.04.007.
46. Mobley, H. L. T., and Alteri, C. J. (2015). Development of a vaccine against Escherichia coli urinary tract infections. Pathogens 5:E1. doi: 10.3390/pathogens5010001.
47. Mohammad, N., Karsabet, M. T., Amani, J., Ardjmand, A., Zadeh, M. R., Gholi, M. K., et al. (2016). In silico design of a chimeric protein containing antigenic fragments of Helicobacter pylori; a bioinformatic approach. Open Microbiol. J. 10, 97-112. doi: 10.2174/1874285801610010097.
48. Molina-López, J., Aparicio-Ozores, G., Ribas-Aparicio, R. M., Gavilanes-Parra, S., Chávez-Berrocal, M. E., Hernández-Castro, R., et al. (2011). Drug resistance, serotypes, and phylogenetic groups among uropathogenic Escherichia coli including O25-ST131 in Mexico City. J. Infect. Dev. Ctries. 5, 840-849. doi: 10.3855/jidc.1703.
49. Moriel, D. G., and Schembri, M. A. (2013). Vaccination approaches for the prevention of urinary tract infection. Curr. Pharm. Biotechnol. 14, 967-974. doi: 10.2174/1389201014666131226144824.
50. Mulvey, M. A., Lopez-Boado, Y. S., Wilson, C. L., Roth, R., Parks, W. C., Heuser, J., et al. (1998). Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282, 1494-1497. doi: 10.1126/science.282.5393.1494.
51. Mulvey, M. A., Schilling, J. D., Martinez, J. J., and Hultgren, S. J. (2000). Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc. Natl. Acad. Sci. U.S.A. 97, 8829-8835. doi: 10.1073/pnas.97.16.8829.
52. Muñoz-Medina, J. E., Sánchez-Vallejo, C. J., Méndez-Tenorio, A., Monroy-Muñoz, I. E., Angeles-Martínez, J., Santos Coy-Arechavaleta, A., et al. (2015). In silico identification of highly conserved epitopes of influenza A H1N1, H2N2, H3N2, and H5N1 with diagnostic and vaccination potential. Biomed Res. Int. 2015:813047. doi: 10.1155/2015/813047.
53. Nayak, S. K., O'Toole, C., and Price, Z. H. (1977). A cell line from an anaplastic transitional cell carcinoma of human urinary bladder. Br. J. Cancer 35, 142-151.
54. Nazarian, S., Mousavi Gargari, S. L., Rasooli, I., Amani, J., Bagheri, S., and Alerasool, M. (2012). An in silico chimeric multi subunit vaccine targeting virulence factors of enterotoxigenic Escherichia coli (ETEC) with its bacterial inbuilt adjuvant. J. Microbiol. Methods 90, 36-45. doi: 10.1016/j.mimet.2012.04.001.
55. Norinder, B. S., Köves, B., Yadav, M., Brauner, A., and Svanborg, C. (2012). Do Escherichia coli strains causing acute cystitis have a distinct virulence repertoire? Microb. Pathog. 52, 10-16. doi: 10.1016/j.micpath.2011.08.005.
56. Olsén, A., Herwald, H., Wikström, M., Persson, K., Mattsson, E., and Björck, L. (2002). Identification of two protein-binding and functional regions of curli, a surface organelle and virulence determinant of Escherichia coli. J. Biol. Chem. 277, 34568-34572. doi: 10.1074/jbc.M206353200.
57. Pedersen-Lane, J., Maley, G. F., Chu, E., and Maley, F. (1997). High-level expression of human thymidylate synthase. Protein Expr. Purif. 10, 256-262. doi: 10.1006/prep.1997.0750.
58. Pedretti, A., Villa, L., and Vistoli, G. (2004). VEGA-an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming. J. Comput. Aided Mol. Des. 18, 167-173. doi: 10.1023/B:JCAM.0000035186.90683.f2.
59. Puigbò, P., Guzmán, E., Romeu, A., and Garcia-Vallvé, S. (2007). OPTIMIZER: a web server for optimizing the codon usage of DNA sequences. Nucleic Acids Res. 35, W126-W131. doi: 10.1093/nar/gkm219.
60. Rapsinski, G. J., Wynosky-Dolfi, M. A., Oppong, G. O., Tursi, S. A., Wilson, R. P., Brodsky, I. E., et al. (2015). Toll-like receptor 2 and NLRP3 cooperate to recognize a functional bacterial amyloid, curli. Infect. Immun. 83, 693-701. doi: 10.1128/IAI.02370-14.
61. Rene, P., Dinolfo, M., and Silverblatt, F. J. (1982). Serum and urogenital antibody responses to Escherichia coli pili in cystitis. Infect. Immun. 38, 542-547.
62. Rene, P., and Silverblatt, F. J. (1982). Serological response to Escherichia coli pili in pyelonephritis. Infect. Immun. 37, 749-754.
63. Saldaña, Z., Xicohtencatl-Cortes, J., Avelino, F., Phillips, A. D., Kaper, J. B., Puente, J. L., et al. (2009). Synergistic role of curli and cellulose in cell adherence and biofilm formation of attaching and effacing Escherichia coli and identification of Fis as a negative regulator of curli. Environ. Microbiol. 11, 992-1006. doi: 10.1111/j.1462-2920.2008.01824.x.
64. Savar, N. S., Jahanian-Najafabadi, A., Mahdavi, M., Shokrgozar, M. A., Jafari, A., and Bouzari, S. (2014). In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections. J. Biotechnol. 175, 31-37. doi: 10.1016/j.jbiotec.2014.01.037.
65. Scott, V. C. S., Haake, D. A., Churchill, B. M., Justice, S. S., and Kim, J.-H. (2015). Intracellular bacterial communities: a potential etiology for chronic lower urinary tract symptoms. Urology 86, 425-431. doi: 10.1016/j.urology.2015.04.002.
66. Secretaria de Salud (2009). Panorama Epidemiológico de las Infecciones de Vías Urinarias en México 2003-2008. Available online at: http://www.epidemiologia.salud.gob.mx/doctos/boletin/2009/sem51.pdf.
67. Sen, T. Z., Jernigan, R. L., Garnier, J., and Kloczkowski, A. (2005). GOR V server for protein secondary structure prediction. Bioinformatics 21, 2787-2788. doi: 10.1093/bioinformatics/bti408.
68. Seras-Franzoso, J., Peternel, S., Cano-Garrido, O., Villaverde, A., and García-Fruitós, E. (2015). Bacterial inclusion body purification. Methods Mol. Biol. 1258, 293-305. doi: 10.1007/978-1-4939-2205-5_16.
69. Serino, L., Moriel, D. G., Rappuoli, R., and Pizza, M. (2010). Towards a vaccine against Escherichia coli-associated urinary tract infections. Future Microbiol. 5, 351-354. doi: 10.2217/fmb.10.6.
70. Shewmaker, F., McGlinchey, R. P., Thurber, K. R., McPhie, P., Dyda, F., Tycko, R., et al. (2009). The functional curli amyloid is not based on in-register parallel beta-sheet structure. J. Biol. Chem. 284, 25065-25076. doi: 10.1074/jbc.M109.007054.
71. Sim, B. C., Zerva, L., Greene, M. I., and Gascoigne, N. R. (1996). Control of MHC restriction by TCR Valpha CDR1 and CDR2. Science 273, 963-966. doi: 10.1126/science.273.5277.963.
72. Sirard, J.-C., Bayardo, M., and Didierlaurent, A. (2006). Pathogen-specific TLR signaling in mucosa: mutual contribution of microbial TLR agonists and virulence factors. Eur. J. Immunol. 36, 260-263. doi: 10.1002/eji.200535777.
73. Sivick, K. E., and Mobley, H. L. T. (2010). Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect. Immun. 78, 568-585. doi: 10.1128/IAI.01000-09.
74. Snyder, J. A., Haugen, B. J., Lockatell, C. V., Maroncle, N., Hagan, E. C., Johnson, D. E., et al. (2005). Coordinate expression of fimbriae in uropathogenic Escherichia coli. Infect. Immun. 73, 7588-7596. doi: 10.1128/IAI.73.11.7588-7596.2005.
75. Spaulding, C. N., and Hultgren, S. J. (2016). Adhesive pili in UTI pathogenesis and drug development. Pathogens 5:E30. doi: 10.3390/pathogens5010030.
76. Sung, M.-A., Fleming, K., Chen, H. A., and Matthews, S. (2001). The solution structure of PapGII from uropathogenic Escherichia coli and its recognition of glycolipid receptors. EMBO Rep. 2, 621-627. doi: 10.1093/embo-reports/kve133.
77. Thankavel, K., Madison, B., Ikeda, T., Malaviya, R., Shah, A. H., Arumugam, P. M., et al. (1997). Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. J. Clin. Invest. 100, 1123-1136. doi: 10.1172/JCI119623.
78. Wang, X., Smith, D. R., Jones, J. W., and Chapman, M. R. (2007). In vitro polymerization of a functional Escherichia coli amyloid protein. J. Biol. Chem. 282, 3713-3719. doi: 10.1074/jbc.M609228200.
79. Wiederstein, M., and Sippl, M. J. (2007). ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35, W407-W410. doi: 10.1093/nar/gkm290.
80. Wilkins, M. R., Gasteiger, E., Bairoch, A., Sanchez, J. C., Williams, K. L., Appel, R. D., et al. (1999). Protein identification and analysis tools in the ExPASy server. Methods Mol. Biol. 112, 531-552.
81. Yang, J., Yan, R., Roy, A., Xu, D., Poisson, J., and Zhang, Y. (2015). The I-TASSER Suite: protein structure and function prediction. Nat. Methods 12, 7-8. doi: 10.1038/nmeth.3213.
82. Zagrovic, B., Jayachandran, G., Millett, I. S., Doniach, S., and Pande, V. S. (2005). How large is an alpha-helix? Studies of the radii of gyration of helical peptides by small-angle X-ray scattering and molecular dynamics. J. Mol. Biol. 353, 232-241. doi: 10.1016/j.jmb.2005.08.053.
83. Zhang, Y., and Skolnick, J. (2005). TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res. 33, 2302-2309. doi: 10.1093/nar/gki524.
84. Zhou, G., Mo, W. J., Sebbel, P., Min, G., Neubert, T. A., Glockshuber, R., et al. (2001). Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J. Cell Sci. 114(Pt 22), 4095-4103.